Tor 20 jun / År 42 / Nr 3 2024

From ex-vivo to in-vivo

Having developed heparin-based solutions to treat devices and organs outside the patient, Corline Biomedical established a subsidiary focused on developing its compounds into drugs that are administered directly into the patient.

If successful, this outside in approach could unlock a large new market potential.

Uppsala-based Corline Biomedical set up Gothenburg-based Corline Pharma in May 2015. Since then, the subsidiary, located in AstraZeneca’s BioVentureHub, has been evaluating totally new indications for the company’s Corline Heparin Conjugate (CHC™) product.
Up to now, CHC has been used successfully in the evolving field of regenerative medicine to improve cell therapies and kidney transplantation. Corline also manufactures and markets heparin-based solutions for surface coatings of medical device implants making them blood and bio-compatible.
Based on the compound’s proven ability to target and anchor to vascular injury sites, the team in Gothenburg has been busy generating and validating a shortlist of potential indications centered around the internal treatment of damaged vasculature.
Henrik Nittmar, CEO for Corline Biomedical, who has been with the company since 2008, sees the expansion of indications as a natural step in the journey the company is on, “We have a proud history where we have learnt and discovered so much about our products. Based on the knowledge and experience we have gained, we are really excited to be gearing up for the future as a company with an increased focus on pharmaceuticals and an increased potential to provide more value – to more patients; to our shareholders; and to the health care industry in general.”
When asked what the critical success factors are when seeking new indications, Stefan Pierrou who works at Corline Pharma responds, “Paramount to success in this business is understanding your compound properties inside out. We are diligently moving towards that goal within Corline Pharma and I strongly believe that with a focus on the right indication we will place ourselves in a very good position to make a difference to both patients and the health care community.”